Lava Therapeutics Nv Expected To Post A Loss Of 51 Cents A Share: Earnings Preview

LAVA Therapeutics NV

12/05/2023 14:32

* LAVA Therapeutics NV  LVTX.OQ   LVTX.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 15
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for LAVA Therapeutics
NV is
for a loss of 51 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 4.4%
in the last three months. ​
    * Wall Street's median 12-month price target for LAVA
Therapeutics
NV is $15​, above​ its last closing price of $1.90. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022              -0.63      -0.57     Beat    10.1
 Sep. 30 2022  0.00        -0.14      0.04      Beat    128.7
 Jun. 30 2022  -0.63       -0.63      -0.31     Beat    50.5​
 Mar. 31 2022  -0.84       -0.86      -0.41     Beat    54.8
 ​​Dec.        -0.41       -0.41      -0.38     Beat    7.8
 31 2021                                                
 Sep. 30 2021  -0.32       -0.31      -0.27     Beat    13.3​
 Jun. 30 2021  -0.27       -0.27      -0.28     Missed  -0.8
 Mar. 31 2021  -0.80       -0.80      -12.27    Missed  -1,432
                                                        .3
 This summary was machine generated May 12 at 13:32 GMT.  All
figures in US dollars  unless otherwise stated